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Abstract
Cardiovascular disease is accountable for around 31% of all deaths worldwide. 
Percutaneous coronary intervention, particularly the use of stents has remarkably 
improved the management of moderate to severe cardiovascular disease since 
its introduction in 1977. However, in approximately 20-30% of patients clinical in-
stent restenosis (ISR) can occur. ISR has a multifactorial aetiology, in which endothelial 
shear stress plays a major role. We aim to review the current evidence assessing the 
relationship between endothelial shear stress and ISR. The introduction of a stent 
can lead to changes in the mechanical environment of the artery, particularly at the 
inlet and the outlet of the stent which are susceptible to areas of low shear stress 
(LSS). In vivo studies have consistently associated LSS with a higher incidence of ISR 
whereas higher shear stress exerts a protective effect. The mechanisms underlying this 
association are not fully known, but ISR is likely to occur through neointimal hyperplasia 
(NIH). An endothelium dependent effect of LSS, endothelium-independent effect of LSS 
or the effect of LSS on smooth muscle cell phenotype may contribute to NIH progression. 
Factors relating to the stent design, patient specific characteristics and mechanical 
factors may also exacerbate NIH formation. Recent advances in the methodology for in 
vivo shear stress profiling may allow the early identification of patients at an increased 
risk of developing ISR clinically. This will then help guide novel treatment strategies 
towards an individual’s needs.
ABBREVIATIONSISR: In-Stent Restenosis; NIH: Neointimal Hyperplasia; PCI: Percutaneous Coronary Intervention, BMS: Bare Metal Stent; 
DES: Drug-Eluting Stent; NF-Κb: Nuclear Factor- Kappa Β; PDGF: 
Platelet-Derived Growth Factor; TNF-Α: Tumour Necrosis Factor 
Alpha; PGI2: Prostacyclin; IL-1: Interleukin-1; KLF-4: Kruppel-
Like Factor 4; LSS: Low Shear Stress; SMC: Smooth Muscle Cell
INTRODUCTION
Shear stress is the force per unit area that occurs when blood 
flow acts on the endothelium [1]. The extent of shear stress can 
be predicted in most vessels by Poiseuille’s law which applies 
to straight and circular tubes of a constant cross-sectional area. 
However, it may not be accurately represented in larger arteries 
as they are not straight, most contain branches that disturb 
steady flow, and the cross-sectional area varies across the artery 
[2-4].
The progression of atherosclerosis can be affected by 
both genetic predispositions and a variety of established 
cardiovascular risk factors [1,5]. The most striking feature of 
atherosclerosis is its geographic distribution along the artery 
tree. The atherosclerotic lesions preferentially occur in the 
arch and bifurcation area while rarely in the straight part [6]. 
According to the local geography, the blood flow patterns and 
forces differ significantly. In the arch and bifurcation area, it is 
disturbed flow with low shear stress [LSS], while in the straight 
it is high shear stress laminar flow [5-8] suggesting flow patterns 
play an important role in atherosclerosis development.
The major consequence of atherosclerosis causes vessel 
narrowing or occlusion, leading to blood supply insufficient or 
ischemia. To combat this, many techniques have been developed. 
Notably, percutaneous coronary intervention (PCI) with stent 
implantation is one of the most common procedures carried out in 
the UK [9]. On average one in three patients with coronary artery 
disease will undergo coronary angioplasty and stenting. Since 
its first use in 1977 by Andrea Gruntzig [10], there have been 
significant developments in the use of stenting. There are two 
main types of stent – bare metal stents (BMS) and drug-eluting 
stents (DES). BMS replaced balloon angioplasty which aided the 
long-term scaffolding of the coronary artery avoiding acute recoil 
and abrupt occlusion. Following this, the introduction of DES has 
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since shown to be an extremely effective treatment, primarily in 
relation to reducing but not eradicating the risk of restenosis [9].
Although these interventions have been successfully used 
worldwide, their clinical benefit may be compromised by the 
occurrence of in-stent restenosis (ISR) and stent thrombosis. 
The prevalence of ISR varies widely in different groups, however 
commonly 20-30% of patients are known to have ISR following 
implantation after 6-12 months [11,12]. Using procedures such as 
intravascular ultrasound [11], coronary angiography [12] as well 
as three-dimensional reconstruction of the artery during routine 
follow-ups [13,14], luminal changes were observed. Recently, it 
was shown that following successful PCI, higher differences in 
the corrected QT dispersion during their pre-and post-repeated 
PCI may be used as a predictor of restenosis [15]. Nevertheless, 
the underlying mechanism of ISR still unknown. While these 
complications may be attributed to patient-specific factors 
such as comorbidities or medication (anti-platelet therapies), 
haemodynamic factors, particularly LSS, the focus of this review, 
are now being shown to be important in the incidence of post 
stenting complications alongside the aforementioned established 
risk factors [1,16,17].
The mechanical implications of stented arteries
The introduction of a stent has profound effects on the 
stresses in the arterial wall, which may affect outcomes post 
intervention. As well as the high pressures that are used when 
introducing stents [18], balloon inflation can damage endothelial 
cells, compromising the integrity of the diseased artery [19]. 
Macroscopically, the segment undergoing intervention will 
return to approximately the three-dimensional shape that was 
present before the invasion of the plaque. This may re-establish 
the original low and oscillating shear stress favouring further 
inflammation and proliferation [17]. Studies using computational 
fluid dynamics [20] have shown that the introduction of stent 
may increase the local curvature at both the inlet and outlet of 
the stent [17,21,22]. Changes in shear stress are found near stent 
edges [22], indicating the possibility that the high curvature 
regions [near the stent edges] may induce separation zones, 
resulting in regions of LSS. In addition to this, the entrance and 
exit edges of the stent will be exposed to increased levels of 
tension due to the difference in stiffness between the artery and 
the stent [19]. Furthermore, the design of the stent strut including 
the thickness and height can lead to disturbances in blood flow 
resulting in small regions of disturbed shear stress [23]. This is 
especially true if the strut is placed at right angles (orthogonal) to 
the blood flow. These factors of stent design favour areas of blood 
stagnation, rendering these more susceptible to thrombosis and 
smooth muscle cell (SMC) proliferation, an important constituent 
of neointimal hyperplasia (NIH) [24].
LSS and ISR
The precise pathophysiological mechanism governing 
ISR remains unknown, however there is strong evidence 
suggesting that NIH is the major mechanism. This process 
usually occurs within or at the edges of the stent, classically due 
to the proliferation and migration of vascular SMCs [25]. NIH 
is a multifaceted process that involves the immediate action of 
platelets, as well as endothelial and SMCs. Although NIH can 
be influenced by direct insult by stent struts or endothelial 
dysfunction [26], the association with shear stress is an important 
determinant [19,27]. Low wall shear stress may promote NIH, 
causing structural change of vessels (increased inflammation and 
increased SMC proliferation) which leads to a decrease in lumen 
size, while a higher shear stress may oppose these effects.
In vivo studies support the hypothesis of a haemodynamic 
mechanism contributing to in-stent NIH. Carlier et al. introduced 
a flow divider (increasing shear stress) randomly in one of 
two stents placed in external iliac arteries of rabbits which 
corresponded to a reduction in NIH [28]. This association was 
similarly found where NIH occurred in regions where there were 
lowest initial values of shear stress in rabbit iliac arteries [29]. 
In addition, NIH occurred most in regions where blood flow was 
disturbed (adjacent to stent struts) and in regions where there 
were acute elevated gradients in shear stress at implantation. 
These studies show that modelling the regions susceptible to LSS 
could predict the distribution of ISR. However, the magnitude of 
shear stress at baseline may not be associated with the magnitude 
of ISR that requires further intervention at follow up [30].
While these in vivo studies do provide insight into 
mechanistic explanations, the direct clinical extrapolation to 
humans may be limited [29,31,32]. The first human findings 
after BMS implantation showed a significant inverse correlation 
between variations of NIH and the magnitude of shear stress 
[20]. However, these results are limited by the design of the study 
in that only patients with no clinically defined restenosis were 
studied (mild form of NIH), therefore whether similar results 
would be found in patients with restenosis is unknown. The first 
serial study carried out on humans showed that evidence of ISR 
occurred in each category of shear stress at baseline, showing no 
inverse correlation as found in animal studies [13]. Similarly, a 
study in 506 patients showed that although NIH is independently 
associated with LSS within the stented region, the magnitude of 
shear stress at baseline is not associated with ISR and further 
intervention [30]. These inconsistent results between shear 
stress and NIH in humans may be due to the differences in 
methodology in measuring flow (computational flow dynamics vs 
displacement of contrast material). More recent studies [33,14] 
have consistently showed an inverse relationship between 
shear stress and restenosis via NIH following BMS implantation 
although the magnitude of this relationship may be weaker 
than originally thought. This suggests that other factors such as 
inflammation, lesion complexity and patient comorbidities may 
also be contributing to this relationship.
Recent studies have focused on the association between shear 
stress and ISR in DES. Overall, DES have been shown to inhibit 
levels of NIH and reduce restenosis rates [9,11,34]. ISR occurred 
more commonly in regions of LSS following both sirolimus-
eluting stent [35] and paclitaxel-eluting stent [36] deployment. 
In contrast to these results, in diabetic patient population 
treated with sirolimus-eluting stents, there was no significant 
association between shear stress and NIH at the stent segments 
[37]. This is likely to be due to other factors (hyperglycaemia and 
hyperinsulinemia can accelerate restenosis) other than shear 
stress that are governing the arterial wall response following 
intervention.
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Mechanisms of in-stent restenosis
The mechanism of restenosis is related to the type of stent 
used, as well as other known risk factors relating to the patient 
or the disease [38]. Pathologically it is evident that there are 
considerable differences between ISR occurring following BMS 
and DES implantation [16]. The key difference is that ISR following 
BMS is characterised by NIH consisting of a proteoglycan rich 
matrix and more vascular SMCs, compared to fewer SMCs in DES 
[39]. Following BMS implantation, the endothelium is restored 
within weeks, LSS may promote ISR through interactions of 
endothelial cells and SMCs. On the other hand, DES attenuate 
vascular SMC proliferation (by pharmacological measures) hence 
reducing the likelihood of ISR [9,38]. In DES, shear stress may 
act directly on SMCs via endothelium independent mechanisms. 
There are three distinct mechanisms for the pathobiology of 
restenosis: endothelium-dependent effect of LSS, endothelium-
independent effect of LSS or the effect of LSS on SMC phenotype 
[16].
LSS promotes inflammatory activation and apoptosis 
of endothelial cells, while high shear stress exerts more 
protective effects [19]. LSS leads to a recruitment of circulatory 
inflammatory cells, particularly monocytes which migrate into 
the intima [16,19,40]. This process is dependent on nitric oxide 
(NO)-regulated activation transcription factors such as nuclear 
factor-kappa β (NF-κB) [41]. The endothelium-independent 
effect of LSS involves SMCs which are responsive to changes in 
shear stress. Shear stress differentially regulates the activity 
of mitogenic molecules such as PDGF and vascular endothelial 
growth factor [42]. Protective high shear stress inhibits smooth 
muscle proliferation through the upregulation of anti- mitogenic 
factors, such as transforming growth factor beta (TGF-β), which 
inhibits DNA synthesis arresting the cell cycle at G1 phase [43]. 
In contrast, LSS may lead to the formation of mitogen gradients, 
triggering SMC migration and proliferation [16,40]. Although the 
exact mechanism is unknown, PDGF has been shown to activate 
several downstream signalling pathways, including Src (a proto-
oncogene tyrosine kinase) and Ire1α/Xbp1 splicing [40,44]
Shear stress can also affect SMC phenotype. During restenosis, 
it is thought that vascular SMCs modulate their physiological 
contractile phenotype to a pathologic synthetic phenotype 
leading to migration into the intima and contributing to arterial 
thickening and narrowing of the lumen [16]. They release 
pro-inflammatory factors and interact with endothelial cells, 
producing more extracellular matrix proteins such as collagen, 
and proteoglycans [45]. Additionally, arterial regions that are 
exposed to LSS contain plaques with a reduced smooth muscle 
content and marked smooth muscle phenotypic modulation 
which promotes the formation of unstable plaques, through 
upregulation of PDGF and Kruppel like factor 4 (KLF 4), SMC 
differentiation inhibitors [46,47].
Factors that affect LSS mediated restenosis
1)  Stent type and drug: Many factors have been found to 
affect the relationship between shear stress and ISR (Table 1). 
There are two main types of stent, BMS and DES. BMS were used to reduce the early elastic recoil, however, ISR was a 
common finding upon medium and long term follow up, due 
to the proliferation and migration of vascular smooth muscle 
cells [endothelium-dependent process] [22]. NIH is likely to 
be favoured in BMS by the sustained LSS that occurs following 
restenosis [8].
The introduction of DES decreased rates of ISR, primarily 
by inhibiting inflammation and vascular SMC proliferation 
pharmacologically [9]. This creates a more favourable 
haemodynamic environment within the artery. The stent 
drug used in DES may affect the incidence of restenosis. Most 
commonly sirolimus and paclitaxel have been used, however 
the pathways in which they inhibit SMC proliferation differs. 
The LSS-activated cyclin-dependent kinase contributes to SMC 
proliferation, sirolimus decreases the cyclin-dependent kinase 
activity arresting cell cycle at G1 phase, suggesting that this may 
be the main mechanism of sirolimus antagonising LSS-mediated 
restenosis [16,48]. Paclitaxel binds to microtubules and prevents 
their depolymerisation which inhibits SMC proliferation 
independently of shear stress related pathways [11]. There may 
be a clinical benefit of choosing sirolimus over paclitaxel elution 
as it leads to lower rates of revascularization in the total patient 
population [49]. In addition, both in vivo and in vitro studies have 
shown that sirolimus elution favours a contractile SMC phenotype, 
whereas paclitaxel promotes a synthetic SMC phenotype [50,51]. 
Consequently, sirolimus attenuates and paclitaxel amplifies the 
LSS associated synthetic phenotype which can contribute to 
restenosis.
2)  Stent design: The stent design may also contribute to a 
diminished restenotic effect, as LSS areas with disturbed flow are 
Table 1: The risk factors for in-stent restenosis.
Risk factor Effect on ISR incidence or predicted
effect via changes in shear stress
Patient related factors
Male sex Increase [59]Increasing age Increase [60]
Diabetes Increase [61]
Renal failure Increase or unchanged [62]Acute coronary syndrome Increase [60]
Stent typeBMS Increase [20-40%] [11]DES Decrease [3-20%] [11]
Stent drugSirolimus Attenuated [11]
Paclitaxel Unchanged [11,16,48]
Stent design
Thick strut Increase [52]
Streamline [circular arc] strut Decrease [23]
Oversizing [>20%] Increase [16]
Undersizing [<5%] Increase [55]
Undersizing [>20%] Decrease [55]
Abbreviations: BMS: Bare Metal Stent; DES: Drug-Eluting Stent; ISR: In-Stent Restenosis
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often found distal to stent struts [24]. This leads to an increase 
in the concentration of the drug compound leading to an anti-
proliferative effect in an area that is susceptible to LSS [16]. The 
thickness of the strut and the shape can affect the possibility of 
strut-induced flow disruption post intervention. Thicker struts 
increase the area within the stent that is exposed to disturbed 
flow and lower shear stress. On the other hand, thin struts with 
larger strut spacing restore shear stress to normal levels. Clinical 
studies have found that stents with thinner struts tend to elicit a 
lower incidence of ISR compared to a thicker strut [52,53].
Areas of LSS are pronounced with non-streamlined struts 
(rectangular) whilst they are reduced with streamlined strut 
(circular arc shape) [23]. A streamlined design can minimalize 
recirculation zones and establish a protective low environment 
with better haemodynamic performance [54]. On the other 
hand, a non-streamlined strut will promote recirculation zones 
and high shear stress peaks which can activate platelet activity. 
Improvements to its design by decreasing the height can be made 
which lessens the effect of the height on the flow [23]. The diameter 
of the stent employed may affect ISR. Often clinically there is a 
propensity to increase the size of stents by approximately 10% 
more than is required to ensure accurate aligning and positioning. 
Gross oversizing (over 20%) of stents was found to be a strong 
stimulant of the restenotic process (direct damage) compared to 
stents that were only slightly oversized [16,55]. The oversized 
stents may also promote NIH by inducing changes in flow rate 
and increasing disturbed flow with LSS in the stented region. On 
the other hand, undersizing stents may lower shear stress near 
strut edges. A small decrease in stent diameter creates small gaps 
between struts and the arterial wall, increasing the resistance to 
flow and thus lowers the shear stress in that region. This effect 
becomes less obvious when there is gross undersizing (20%) due 
to the increased distance between the strut and the arterial wall 
which decreases the flow resistance, therefore LSS regions are 
less likely to develop [52,56]. However, the degree of undersizing 
affects the occurrence of restenosis with a nonlinear relationship 
between undersizing and shear stress [52,53,56,57].
CLINICAL IMPLICATIONS AND CONCLUSION
Although PCI has revolutionized the treatment of 
cardiovascular disease, the extent of complications occurring 
cannot be underestimated. The introduction of DES has led to 
a decrease in the incidence of ISR compared to BMS. However, 
restenosis still occurs in this population group due to biological, 
mechanical or technical factors. To improve clinical outcomes, it 
would be ideal to individualize interventions having considered 
the stent type and design. Recent advances in the methodology in particular in vivo profiling may become suitable for use in a 
clinical setting [58-62]. By being able to model stented segments 
that are particularly susceptible to LSS, this will allow the 
identification of individual patients who are at an increased risk 
of the development of complications [16], whilst also allowing 
prognostic insight into how lesions may develop or change over 
time. Here, we reviewed the role of LSS in the pathogenesis of 
ISR, occurring via NIH. Whilst the exact mechanisms responsible 
for endothelial cell function and repair post stenting are not well 
understood, this may occur via an endothelium-dependent or an 
endothelium-independent manner. Thus, further investigation is 
warranted concerning both the fundamental science as well as 
the clinical impact in order to understand and assist the potential 
development of therapies that will aim to reduce ISR.
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